Logotype for Yarrow Bioscience Inc

Yarrow Bioscience (YARW) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Yarrow Bioscience Inc

Q3 2026 earnings summary

13 Nov, 2026

Executive summary

  • YB-101 is an anti-TSHR antibody for Graves’ disease (GD) and thyroid eye disease (TED); the DIRECTION-GD Phase 2a/2b trial is underway, with Phase 2a topline results expected in H2 2027.

  • FDA cleared the GD investigational new drug application in March 2026 and granted Fast Track designation on May 20, 2026.

  • The first patient has been dosed in the randomized, blinded, placebo-controlled Phase 2a trial; enrollment is ongoing.

Financial highlights

  • Q3 2026 R&D and G&A expenses were $5.3M and $5.5M; operating loss was $10.7M and net loss was $9.7M.

  • For 9M 2026, R&D and G&A expenses were $11.5M and $8.8M; operating loss was $20.3M and net loss was $19.0M.

  • Other income, primarily interest, was $1.0M in Q3 and $1.3M for 9M 2026; no comparative 2025 periods are presented.

Outlook and guidance

  • Cash at September 30, 2026 is expected to fund operations into 2030, including DIRECTION-GD and preparation for a planned TED study; the estimate depends on assumptions that may change.

  • DIRECTION-GD Phase 2a topline results are expected in H2 2027; the trial evaluates safety, PK, PD and efficacy through 24 weeks.

  • Phase 2b is expected to begin enrolling in H1 2028 as a dose-finding study of ~200 patients, with dose selection informed by Phase 2a data.

  • GenSci’s Phase 1 TED multiple-ascending-dose data are expected in H2 2027 and to inform global TED development plans.

  • R&D costs are expected to rise as YB-101 advances; G&A is expected to increase with headcount, public-company costs and IP activity.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Yarrow Bioscience